Literature DB >> 2554168

Excitatory amino acids and Alzheimer's disease.

J T Greenamyre1, A B Young.   

Abstract

Excitatory amino acids (EAA) such as glutamate and aspartate are major transmitters of the cerebral cortex and hippocampus, and EAA mechanisms appear to play a role in learning and memory. Anatomical and biochemical evidence suggests that there is both pre- and postsynaptic disruption of EAA pathways in Alzheimer's disease. Dysfunction of EAA pathways could play a role in the clinical manifestations of Alzheimer's disease, such as memory loss and signs of cortical disconnection. Furthermore, EAA might be involved in the pathogenesis of Alzheimer's disease, by virtue of their neurotoxic (excitotoxic) properties. Circumstantial evidence raises the possibility that the EAA system may partially determine the distribution of pathology in Alzheimer's disease and may be important in producing the neurofibrillary tangles, RNA reductions and dendritic changes which characterize this devastating disorder. In this article, we will review the evidence suggesting a role for EAA in the clinical manifestations and pathogenesis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554168     DOI: 10.1016/0197-4580(89)90143-7

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  70 in total

1.  Treatment of Alzheimer's disease.

Authors:  D M Bowen; P T Francis; A W Procter; A B Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-04       Impact factor: 10.154

Review 2.  New developments on the role of NMDA receptors in Alzheimer's disease.

Authors:  Roberto Malinow
Journal:  Curr Opin Neurobiol       Date:  2011-09-29       Impact factor: 6.627

Review 3.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Presenilin-1/γ-secretase controls glutamate release, tyrosine phosphorylation, and surface expression of N-methyl-D-aspartate receptor (NMDAR) subunit GluN2B.

Authors:  Zhao Xuan; Gael Barthet; Junichi Shioi; Jindong Xu; Anastasios Georgakopoulos; Julien Bruban; Nikolaos K Robakis
Journal:  J Biol Chem       Date:  2013-09-11       Impact factor: 5.157

5.  Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA receptor antagonist.

Authors:  D D Schoepp; P L Ornstein; C R Salhoff; J D Leander
Journal:  J Neural Transm Gen Sect       Date:  1991

6.  Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms.

Authors:  S Caccia; S Confalonieri; G Guiso; P Bernasconi; A Cagnotto; M Skorupska; T Mennini
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

7.  Can zebrafish be used as animal model to study Alzheimer's disease?

Authors:  Soraya Santana; Eduardo P Rico; Javier S Burgos
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

Review 8.  Glutamate: its role in learning, memory, and the aging brain.

Authors:  W J McEntee; T H Crook
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors.

Authors:  Angela M Floden; Shanshan Li; Colin K Combs
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

Review 10.  Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits.

Authors:  J Raber
Journal:  Mol Neurobiol       Date:  1998-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.